154 related articles for article (PubMed ID: 23319326)
1. Elevated levels of mitochondrial mortalin and cytosolic HSP70 in blood as risk factors in patients with colorectal cancer.
Rozenberg P; Kocsis J; Saar M; Prohászka Z; Füst G; Fishelson Z
Int J Cancer; 2013 Jul; 133(2):514-8. PubMed ID: 23319326
[TBL] [Abstract][Full Text] [Related]
2. Circulating mitochondrial stress 70 protein/mortalin and cytosolic Hsp70 in blood: Risk indicators in colorectal cancer.
Jubran R; Kocsis J; Garam N; Maláti É; Gombos T; Barabás L; Gráf L; Prohászka Z; Fishelson Z
Int J Cancer; 2017 Dec; 141(11):2329-2335. PubMed ID: 28791678
[TBL] [Abstract][Full Text] [Related]
3. High levels of acute phase proteins and soluble 70 kDa heat shock proteins are independent and additive risk factors for mortality in colorectal cancer.
Kocsis J; Mészáros T; Madaras B; Tóth EK; Kamondi S; Gál P; Varga L; Prohászka Z; Füst G
Cell Stress Chaperones; 2011 Jan; 16(1):49-55. PubMed ID: 20730518
[TBL] [Abstract][Full Text] [Related]
4. Circulating mortalin in blood and activation of the alternative complement pathway as risk indicators in COVID-19 infection.
Avraham M; Sinkovits G; Hurler L; Prohászka Z; Fishelson Z
Front Immunol; 2024; 15():1337215. PubMed ID: 38715618
[TBL] [Abstract][Full Text] [Related]
5. High serum Hsp70 level predicts poor survival in colorectal cancer: Results obtained in an independent validation cohort.
Gráf L; Barabás L; Madaras B; Garam N; Maláti É; Horváth L; Prohászka Z; Horváth Z; Kocsis J
Cancer Biomark; 2018; 23(4):539-547. PubMed ID: 30452400
[TBL] [Abstract][Full Text] [Related]
6. The clinicopathological significance of Mortalin overexpression in invasive ductal carcinoma of breast.
Jin H; Ji M; Chen L; Liu Q; Che S; Xu M; Lin Z
J Exp Clin Cancer Res; 2016 Mar; 35():42. PubMed ID: 26955804
[TBL] [Abstract][Full Text] [Related]
7. TP53 status regulates ACSL5-induced expression of mitochondrial mortalin in enterocytes and colorectal adenocarcinomas.
Klaus C; Kaemmerer E; Reinartz A; Schneider U; Plum P; Jeon MK; Hose J; Hartmann F; Schnölzer M; Wagner N; Kopitz J; Gassler N
Cell Tissue Res; 2014 Jul; 357(1):267-78. PubMed ID: 24770931
[TBL] [Abstract][Full Text] [Related]
8. Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival.
Dundas SR; Lawrie LC; Rooney PH; Murray GI
J Pathol; 2005 Jan; 205(1):74-81. PubMed ID: 15532096
[TBL] [Abstract][Full Text] [Related]
9. Cytoplasmic sequestration of the tumor suppressor p53 by a heat shock protein 70 family member, mortalin, in human colorectal adenocarcinoma cell lines.
Gestl EE; Anne Böttger S
Biochem Biophys Res Commun; 2012 Jun; 423(2):411-6. PubMed ID: 22683628
[TBL] [Abstract][Full Text] [Related]
10. Complement triggers relocation of Mortalin/GRP75 from mitochondria to the plasma membrane.
Mazkereth N; Rocca F; Schubert JR; Geisler C; Hillman Y; Egner A; Fishelson Z
Immunobiology; 2016 Dec; 221(12):1395-1406. PubMed ID: 27475989
[TBL] [Abstract][Full Text] [Related]
11. Hsp70--a biomarker for tumor detection and monitoring of outcome of radiation therapy in patients with squamous cell carcinoma of the head and neck.
Gehrmann M; Specht HM; Bayer C; Brandstetter M; Chizzali B; Duma M; Breuninger S; Hube K; Lehnerer S; van Phi V; Sage E; Schmid TE; Sedelmayr M; Schilling D; Sievert W; Stangl S; Multhoff G
Radiat Oncol; 2014 Jun; 9():131. PubMed ID: 24912482
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 70 is a useful marker for predicting colorectal cancer.
Gunaldi M; Kocoglu H; Okuturlar Y; Gedikbasi A; Karabulut M; Alis H; Hursitoglu M
J BUON; 2015; 20(6):1464-70. PubMed ID: 26854442
[TBL] [Abstract][Full Text] [Related]
13. Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity.
Pilzer D; Saar M; Koya K; Fishelson Z
Int J Cancer; 2010 Mar; 126(6):1428-35. PubMed ID: 19739077
[TBL] [Abstract][Full Text] [Related]
14. Validation of heat shock protein 70 as a tumor-specific biomarker for monitoring the outcome of radiation therapy in tumor mouse models.
Bayer C; Liebhardt ME; Schmid TE; Trajkovic-Arsic M; Hube K; Specht HM; Schilling D; Gehrmann M; Stangl S; Siveke JT; Wilkens JJ; Multhoff G
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):694-700. PubMed ID: 24521683
[TBL] [Abstract][Full Text] [Related]
15. Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis.
Pilzer D; Fishelson Z
Int Immunol; 2005 Sep; 17(9):1239-48. PubMed ID: 16091382
[TBL] [Abstract][Full Text] [Related]
16. Mortalin peptides exert antitumor activities and act as adjuvants to antibody-mediated complement-dependent cytotoxicity.
Jubran R; Saar-Ray M; Wawruszak A; Ziporen L; Donin N; Bairey O; Fishelson Z
Int J Oncol; 2020 Oct; 57(4):1013-1026. PubMed ID: 32700755
[TBL] [Abstract][Full Text] [Related]
17. Involvement of mortalin/GRP75/mthsp70 in the mitochondrial impairments induced by A53T mutant α-synuclein.
Liu FT; Chen Y; Yang YJ; Yang L; Yu M; Zhao J; Wu JJ; Huang F; Liu W; Ding ZT; Wang J
Brain Res; 2015 Apr; 1604():52-61. PubMed ID: 25665531
[TBL] [Abstract][Full Text] [Related]
18. Mortalin (GRP75/HSPA9) Promotes Survival and Proliferation of Thyroid Carcinoma Cells.
Starenki D; Sosonkina N; Hong SK; Lloyd RV; Park JI
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027376
[TBL] [Abstract][Full Text] [Related]
19. Cooperation between Hsp90 and mortalin/GRP75 in resistance to cell death induced by complement C5b-9.
Rozenberg P; Ziporen L; Gancz D; Saar-Ray M; Fishelson Z
Cell Death Dis; 2018 Feb; 9(2):150. PubMed ID: 29396434
[TBL] [Abstract][Full Text] [Related]
20. CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer.
Kawamura M; Toiyama Y; Tanaka K; Saigusa S; Okugawa Y; Hiro J; Uchida K; Mohri Y; Inoue Y; Kusunoki M
Eur J Cancer; 2012 Sep; 48(14):2244-51. PubMed ID: 22197219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
